The PFS benefit for Enhertu plus pertuzumab versus THP was consistent across subgroups ... approved and promising compounds in development that leverage different mechanisms of action to address the ...

Pertuzumab, a monoclonal antibody, is used in combination with trastuzumab and other chemotherapeutics to treat HER2-positive breast cancer. The mechanism of its action is to block the HER2 receptor, ...

The question of putative mechanisms of action continues to haunt psychopharmacology. Put simply, we know these drugs work, but we have very little idea how. We make guesses based on the ...

Investigator-assessed PFS demonstrated a median PFS of 40.7 months for ENHERTU plus pertuzumab compared to 20.7 months for THP (HR 0.49; 95% CI 0.39-0.61; nominal p-value <0.00001). Confirmed ...

Investigator-assessed PFS demonstrated a median PFS of 40.7 months for ENHERTU plus pertuzumab compared to 20.7 months for THP (HR 0.49; 95% CI 0.39-0.61; nominal p-value <0.00001). Confirmed ...

Mechanism of action describes the process by which a molecule, such as a drug, functions to produce a pharmacological effect. A drug’s mechanism of action may refer to its effects on a ...

(RTTNews) - CytoDyn Inc. (CYDY.OB), a biotechnology company, Tuesday announced new data suggesting a novel mechanism of action of leronlimab for the treatment of solid tumors. CytoDyn analyzed ...

"This preliminary work opens exciting avenues for future research to clarify the underlying mechanisms and to develop new improved therapies focusing on increasing energy expenditure for long-term ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

The APHINITY study confirmed significant overall survival benefits of a Perjeta-based regimen in HER2-positive early-stage breast cancer, especially for lymph node-positive patients. Ten-year data ...

Adding adjuvant pertuzumab to standard adjuvant chemotherapy and trastuzumab improved overall survival at 11 years of follow-up in patients with early human epidermal growth factor receptor 2 ...